Navigation Links
Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT
Date:10/22/2010

of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our pro
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... Florida (PRWEB) December 19, 2014 Sub Zero ... to sponsor a blood drive Sunday the 28th from 2pm-6pm ... Road & Sawyer Road in Sarasota, FL. , Inquiries regarding ... thank you for participating in the donating process, Sub Zero ... free flash frozen, custom ice cream. , About Sub Zero ...
(Date:12/19/2014)... The Plantrician Project , ... events, tools and resources for healthcare professionals and ... the world’s leading online cooking school, have joined ... needs: Culinary Rx. As an online food and ... scheduled for debut spring 2015, will be designed ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3
... NEW ORLEANS -- A research team led by Mayo ... face a more than doubled risk for some types ... Digestive Disease Week 2010, the annual meeting of the ... remains the third-leading cause of cancer deaths among women ...
... C treatment for liver transplant patients beyond current standards results ... the blood, and a low relapse rate, according to a ... who achieved a sustained virological response were more likely to ... gastroenterology fellow at Henry Ford Hospital and lead author of ...
... , ... on May 20, 2010 to learn more about endometriosis, diagnosis and treatment options. ... (PRWEB) May 2, ... organization’s inaugural scientific symposium, “Advancing the Art & Science of Endometriosis: Stem Cells to ...
... It is well-known that children in foster care are at increased ... who live with relatives other than their birth parents? Children ... child welfare agencies, and little research has been done on this ... MD, and her colleagues, used data from a 2007 national survey ...
... Simplifying Medicaid renewal applications may help families ... insurance program, resulting in better medical care, according ... at the Pediatric Academic Societies (PAS) annual meeting ... have shown that literacy-related barriers affect retention in ...
... ... lasik. , ... 2010 -- Visian ICL manufactured by STAAR is a good solution for individuals who have ... many patients had little alternative but to correct their vision with contact lenses or glasses. ...
Cached Medicine News:Health News:Older women with diabetes face higher risk for colon cancer 2Health News:Extended hepatitis C treatment after liver transplant may benefit patients 2Health News:Endometriosis Foundation of America to Present Landmark Scientific Symposium in NYC 2Health News:Children living with relatives struggle with physical, mental health issues 2Health News:Reading level of Medicaid renewal applications often too high 2Health News:Staar Visian ICL Solution to Near Sightedness 2Health News:Staar Visian ICL Solution to Near Sightedness 3Health News:Staar Visian ICL Solution to Near Sightedness 4
... is an enzyme immunometric assay (EIA) ... liquid phase,incubation, designed for the quantitative ... microplate is coated,with anti-rabbit antibodies.,Calibrators and ... antibody-coated wells, along with rabbit anticortisol,antibodies ...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
Medicine Products: